Blockchain Registration Transaction Record

Nutriband CEO to Speak at Nasdaq Biotech Summit

Nutriband CEO Gareth Sheridan to attend Nasdaq LaB Biotech Summit, showcasing AVERSA™ abuse-deterrent technology for fentanyl patches. Learn more about NTRB's innovative transdermal solutions.

Nutriband's participation in the Nasdaq LaB Biotech Summit highlights its ongoing efforts to combat opioid abuse through its AVERSA™ technology. This event provides a unique opportunity for the company to gain visibility among investors and industry leaders, potentially accelerating partnerships and funding for its innovative transdermal products. For the broader biotech community, Nutriband's presence underscores the growing importance of abuse-deterrent technologies in addressing public health crises. The summit also serves as a networking hub that could influence future collaborations and market trends in the biotech sector, making it a significant event for stakeholders to watch.